September 19, 2014—Hospitals across America will begin paying more for the world’s three top-selling cancer drugs starting Oct. 1 due to manufacturer Genentech’s decision to move them into the specialty distribution channel, according to multiple hospital stakeholders.
You must be registered to read complete articles (it's quick, easy, and 100% free). Click here to register.
Already registered? Click here to login. (340B Health members, Drug Discount Monitor subscribers, and 340B Coalition conference attendees: Use your existing username and password.)